In the group that did not take tamoxifen, CYP2D6 genotype could not influence survival, which led to the conclusion that CYP2D6 activity cannot be used as prognostic marker for breast cancer, as it only can estimate the outcome with tamoxifen treatment. This evidence concerns the gene CYP2D6 and breast carcinoma.